Science Explorer Back to mapMap
Discussion
Company · Waltham · United States

Entasis Therapeutics (United States)

entasistx.comROR OpenAlex
Research works
53
▼ 15% vs 2018-21
Citations
1.9k
36.2 per fractional work
Top-10% rate
23.2%
all institutions 10.0%
Open access
73%
world 40%
International
9%
world 18%
Entasis Therapeutics (United States)

Not ranked overall: Entasis Therapeutics (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Entasis Therapeutics (United States) work in?

In all years, 53% of research at Entasis Therapeutics (United States) is in Life Sciences, 40% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (40%), Medicine (39%), Immunology and Microbiology (12%). It does 2.8× the world's share of Life Sciences.

Life Sciences: 28 fractional works · 52.8% of its workBiochemistry, Genetics and Molecular Biology: 21 fractional works · 40.2% of its workMolecular Medicine: 13 fractional works · 24.4% of its workMolecular Biology: 4 fractional works · 7.8% of its workEndocrinology: 2 fractional works · 3.8% of its workGenetics: 1 fractional works · 2.6% of its workClinical Biochemistry: 0 fractional works · 0.6% of its workPhysiology: 0 fractional works · 0.5% of its workCancer Research: 0 fractional works · 0.3% of its workImmunology and Microbiology: 6 fractional works · 12.0% of its workApplied Microbiology and Biotechnology: 5 fractional works · 8.5% of its workMicrobiology: 2 fractional works · 3.4% of its workSmaller subfields together: 0 fractional works · 0.1% of its workAgricultural and Biological Sciences: 0 fractional works · 0.4% of its workPlant Science: 0 fractional works · 0.4% of its workNeuroscience: 0 fractional works · 0.1% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 0.1% of its workHealth Sciences: 22 fractional works · 40.4% of its workMedicine: 21 fractional works · 39.0% of its workPharmacology: 10 fractional works · 17.8% of its workEpidemiology: 4 fractional works · 8.3% of its workInfectious Diseases: 2 fractional works · 4.0% of its workPediatrics, Perinatology and Child Health: 2 fractional works · 3.9% of its workOncology: 1 fractional works · 1.3% of its workPublic Health, Environmental and Occupational Health: 1 fractional works · 1.3% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 0.9% of its workSurgery: 0 fractional works · 0.6% of its workPhysiology: 0 fractional works · 0.4% of its workPulmonary and Respiratory Medicine: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.3% of its workNursing: 0 fractional works · 0.6% of its workNutrition and Dietetics: 0 fractional works · 0.6% of its workVeterinary: 0 fractional works · 0.6% of its workSmall Animals: 0 fractional works · 0.6% of its workHealth Professions: 0 fractional works · 0.1% of its workPhysical Sciences: 3 fractional works · 6.1% of its workEnvironmental Science: 2 fractional works · 3.5% of its workPollution: 2 fractional works · 3.5% of its workMathematics: 0 fractional works · 0.8% of its workModeling and Simulation: 0 fractional works · 0.6% of its workSmaller subfields together: 0 fractional works · 0.2% of its workPhysics and Astronomy: 0 fractional works · 0.6% of its workAtomic and Molecular Physics, and Optics: 0 fractional works · 0.6% of its workChemistry: 0 fractional works · 0.5% of its workOrganic Chemistry: 0 fractional works · 0.3% of its workAnalytical Chemistry: 0 fractional works · 0.2% of its workComputer Science: 0 fractional works · 0.3% of its workSignal Processing: 0 fractional works · 0.3% of its workEngineering: 0 fractional works · 0.3% of its workIndustrial and Manufacturing Engineering: 0 fractional works · 0.3% of its workSocial Sciences: 0 fractional works · 0.7% of its workEconomics, Econometrics and Finance: 0 fractional works · 0.6% of its workEconomics and Econometrics: 0 fractional works · 0.6% of its workPsychology: 0 fractional works · 0.1% of its workALL ITS WORKEntasisTherapeutics…53fractional works, all years
Life Sciences53%Physical Sciences6%Health Sciences40%Social Sciences1%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 17 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology2140.2%
    2. Immunology and Microbiology612.0%
    3. Agricultural and Biological Sciences00.4%
    4. Neuroscience00.1%
    5. Pharmacology, Toxicology and Pharmaceutics00.1%
    1. Medicine2139.0%
    2. Nursing00.6%
    3. Veterinary00.6%
    4. Health Professions00.1%
    1. Environmental Science23.5%
    2. Mathematics00.8%
    3. Physics and Astronomy00.6%
    4. Chemistry00.5%
    5. Computer Science00.3%
    6. Engineering00.3%
    1. Economics, Econometrics and Finance00.6%
    2. Psychology00.1%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 5.99× its world share, 6 worksBiochemistry, Geneti…Immunology and Microbiology: 16.64× its world share, 3 worksImmunology and Micro…Pharmacology, Toxicology and Pharmaceutics: 0.88× its world share, 0 worksPharmacology, Toxico…Environmental Science: 0.38× its world share, 0 worksEnvironmental ScienceMathematics: 1.98× its world share, 0 worksMathematicsMedicine: 2.34× its world share, 8 worksMedicineEconomics, Econometrics and Finance: 0.87× its world share, 0 worksEconomics, Econometr…1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 16.6×. Every wedge is a field page.

All 7 fields, with their numbers
  1. Immunology and Microbiology16.64×3 works
  2. Biochemistry, Genetics and Molecular Biology5.99×6 works
  3. Medicine2.34×8 works
  4. Mathematics1.98×0 works
  5. Pharmacology, Toxicology and Pharmaceutics0.88×0 works
  6. Economics, Econometrics and Finance0.87×0 works
  7. Environmental Science0.38×0 works

Who are the top researchers at Entasis Therapeutics (United States)?

Ranked on the quality score, Alita A. Miller, John P. O’Donnell and Samir H. Moussa lead among researchers whose main affiliation is Entasis Therapeutics (United States).

  1. 1 Alita A. Miller United States · #213,780 worldwide 4.7k citations · 89 works
  2. 2 John P. O’Donnell United States · #242,572 worldwide 3.8k citations · 60 works
  3. 3 Samir H. Moussa United States · #306,362 worldwide 1.7k citations · 52 works
  4. 4 John P. Mueller United States · #452,156 worldwide 3.9k citations · 74 works
  5. 5 Sarah M. McLeod United States · #453,448 worldwide 2.3k citations · 72 works
  6. 6 Rubén Tommasi United States · #666,167 worldwide 3.5k citations · 60 works
  7. 7 Ramkumar Iyer United States · #1,010,790 worldwide 1.3k citations · 18 works
  8. 8 Nicole Carter United States · #1,447,625 worldwide 912 citations · 31 works
  9. 9 David Altarac United States · #1,962,991 worldwide 979 citations · 18 works
  10. 10 Drew E. Lewis United States · #2,269,153 worldwide 525 citations · 16 works
All ranked researchers at Entasis Therapeutics (United States)

What are the most cited papers from Entasis Therapeutics (United States)?

The most cited paper from Entasis Therapeutics (United States) is "ESKAPEing the labyrinth of antibacterial discovery" (Rubén Tommasi, Dean G. Brown, Grant K. Walkup et al., 2015), with 628 citations. Next come "Effects of STX209 (Arbaclofen) on Neurobehavioral Function in Children and Adults with Fragile X Syndrome: A Randomized, Controlled, Phase 2 Trial" (328) and "Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)" (316).

Most cited papers
#PaperReleasedCitations
1 ESKAPEing the labyrinth of antibacterial discovery Rubén Tommasi, Dean G. Brown, Grant K. Walkup et al. · Nature Reviews Drug Discovery Review 3 Jul 2015 628
2 Effects of STX209 (Arbaclofen) on Neurobehavioral Function in Children and Adults with Fragile X Syndrome: A Randomized, Controlled, Phase 2 Trial Elizabeth Berry‐Kravis, David R. Hessl, Barbara Rathmell et al. · Science Translational Medicine Open access 19 Sep 2012 328
3 Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK) Keith S. Kaye, Andrew F. Shorr, Richard G. Wunderink et al. · The Lancet Infectious Diseases 11 May 2023 316
4 ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii Thomas F. Durand-Réville et al. · Nature Microbiology 29 Jun 2017 283
5 Reversal of Disease-Related Pathologies in the Fragile X Mouse Model by Selective Activation of GABA B Receptors with Arbaclofen Christina Henderson, Lasani S. Wijetunge, Mika Kinoshita et al. · Science Translational Medicine Open access 19 Sep 2012 251
All 99 most cited papers, with filters and sorting

Which keywords describe research at Entasis Therapeutics (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Antibiotic Resistance, ESKAPE Pathogens, Multidrug-Resistant Bacteria, Antimicrobial Resistance, Epidemiology, Antibiotic Pharmacokinetics, Critically Ill Patients and Drug Resistance.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Antibiotic Resistance21▲ 96×8 topics
  2. ESKAPE Pathogens13▲ 461×1 topic
  3. Multidrug-Resistant Bacteria13▲ 461×1 topic
  4. Epidemiology13▲ 6.0×19 topics
  5. Antimicrobial Resistance12▲ 85×4 topics
  6. Antibiotic Pharmacokinetics8▲ 344×1 topic
  7. Critically Ill Patients8▲ 344×1 topic
  8. Drug Resistance6▲ 34×3 topics
  9. Infectious Diseases6▲ 43×4 topics
  10. Public Health5▲ 6.3×2 topics
  11. Antimicrobial Stewardship4▲ 287×1 topic
  12. Global Health4▲ 65×1 topic
  13. Clinical Practice Guidelines2▲ 8.4×2 topics
  14. Microbial Communities2▲ 14×3 topics
  15. Community-Acquired Pneumonia2▲ 100×1 topic
  16. Pneumococcal Conjugate Vaccine2▲ 100×1 topic
  17. Antibiotics2▲ 50×2 topics
  18. Anticancer2▲ 18×2 topics
  19. Clinical Trials2▲ 5.8×2 topics
  20. Resistance Genes2▲ 91×1 topic
  21. Vaccine Development2▲ 12×3 topics
  22. Virulence2▲ 49×3 topics
  23. Wastewater Contaminants2▲ 91×1 topic
  24. Treatment2▲ 2.6×4 topics
  25. Off-Label Drug Use2▲ 81×1 topic
  26. Pediatric Pharmacokinetics2▲ 81×1 topic
  27. Signal Transduction2▲ 11×2 topics
  28. Cholesterol-lowering1▲ 52×2 topics
  29. Diabetes Mellitus1▲ 11×2 topics
  30. Membrane Proteins1▲ 15×2 topics
  31. Sexually Transmitted Infections1▲ 45×1 topic
  32. Vaginal Microbiome1▲ 83×1 topic
  33. Bacterial Physiology1▲ 50×1 topic
  34. Gene Regulation1▲ 17×1 topic
  35. Anti-inflammatory1▲ 8.1×2 topics
  36. Genetic Variants1▲ 10×2 topics
  37. Type III Secretion System1▲ 34×2 topics
  38. Alkaloids1▲ 28×1 topic
  39. Antiretroviral Therapy1▲ 8.5×2 topics
  40. Berberine1▲ 224×1 topic

Which research topics does Entasis Therapeutics (United States) publish most on?

By volume in 2022-now: Antibiotic Resistance in Bacteria, Antibiotics Pharmacokinetics and Efficacy, Antibiotic Use and Resistance and Pneumonia and Respiratory Infections.

Antibiotic Resistance in…5Antibiotic Resistance in Bacteria: 5 fractional worksAntibiotics Pharmacokine…4Antibiotics Pharmacokinetics and Efficacy: 4 fractional worksAntibiotic Use and Resis…3Antibiotic Use and Resistance: 3 fractional worksPneumonia and Respirator…1Pneumonia and Respiratory Infections: 1 fractional worksBerberine and alkaloids research: 1 fractional worksPharmaceutical studies and practices: 1 fractional worksPharmaceutical and Antibiotic Environmental Impacts: 0 fractional worksPneumocystis jirovecii pneumonia detection and treatment: 0 fractional worksCOVID-19 epidemiological studies: 0 fractional worksPharmaceutical Economics and Policy: 0 fractional works
Molecular MedicinePharmacologyApplied Microbiology and BiotechnologyEpidemiology4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Antibiotic Resistance in Bacteria Molecular Medicine 5 works
  2. 2 Antibiotics Pharmacokinetics and Efficacy Pharmacology 4 works
  3. 3 Antibiotic Use and Resistance Applied Microbiology and Biotechnology 3 works
  4. 4 Pneumonia and Respiratory Infections Epidemiology 1 works
  5. 5 Berberine and alkaloids research Pharmacology 1 works
  6. 6 Pharmaceutical studies and practices Pediatrics, Perinatology and Child Health 1 works
  7. 7 Pharmaceutical and Antibiotic Environmental Impacts Pollution 0 works
  8. 8 Pneumocystis jirovecii pneumonia detection and treatment Epidemiology 0 works
  9. 9 COVID-19 epidemiological studies Modeling and Simulation 0 works
  10. 10 Pharmaceutical Economics and Policy Economics and Econometrics 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available73.0%not open27.0%

World: 40% of research is openly available.

with international co-authors8.9%domestic only91.1%

World: 18% is written across borders.

How has Entasis Therapeutics (United States)'s research output changed?

Output in 2022-2025 was 15% lower than in 2018-2021.

still counting200020052010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Entasis Therapeutics (United States) as a percentage of every work published that year, 0.000061% in 2024.

still counting0.00010%0.00020%Entasis Therapeutics (United States)0.0000071% in 2025200020102020

Fractional works of Entasis Therapeutics (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Waltham

All research institutions in Waltham

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Entasis Therapeutics (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.